PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals announced today the acquisition of the Canadian rights to the oral product line of the antibiotic Vancocin® (vancomycin hydrochloride) from Eli Lilly Canada, an affiliate of Eli Lilly and Company (NYSE:LLY) effective September 11, 2007.
